Table 3:
Association between prospectively-measured, circulating 25(OH)D and cancer mortality, stratified by stagea
| Season-Specific Quintile of Serum 25(OH)Db | ||||||
|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | p-trend | |
| All Cases - Stage 1–2 10=1,0881 | ||||||
| Number of deaths/survivors | 97/103 | 99/121 | 91/109 | 106/129 | 95/138 | |
| Survival time (years, median) | 4.60 | 7.03 | 7.84 | 6.71 | 7.73 | |
| Age-adjusted HR (95% CI)c | 1.00 | 0.78 (0.59–1.03) | 0.74 (0.56–0.99) | 0.73 (0.55–0.96) | 0.63 (0.47–0.83) | 0.003 |
| Multivariate-adjusted HR (95% CI)d | 1.00 | 0.75 (0.57–1.00) | 0.80 (0.60–1.08) | 0.71 (0.53–0.94) | 0.68 (0.50–0.91) | 0.02 |
| All Cases - Stage 3–4 (n= 1,190) | ||||||
| Number of deaths/survivors | 223/35 | 195/37 | 199/32 | 188/42 | 191/48 | |
| Survival time (years, median) | 0.80 | 1.12 | 0.85 | 0.84 | 1.25 | |
| Age-adjusted HR (95% CI)c | 1.00 | 0.88 (0.72–1.06) | 0.99 (0.82–1.20) | 0.88 (0.72–1.06) | 0.76 (0.62–0.92) | 0.01 |
| Multivariate-adjusted HR (95% CI)d | 1.00 | 0.87 (0.72–1.06) | 1.05 (0.86–1.27) | 0.95 (0.78–1.16) | 0.83 (0.68–1.01) | 0.20 |
25(OH)D, 25-hydroxyvitamin D; CI, confidence intervals; HR, hazard ratio
a
Stage data available for 49% of overall cases; p-interaction=0.77
b
Cutpoints for the 25(OH)D concentrations were based on the distribution in each analysis set and season and are reported in Table 2
c
Adjusted for age at diagnosis
d
Additionally adjusted for body mass index, number of cigarettes smoked per day, years of smoking, physical activity, serum cholesterol, history of diabetes, family history of cancer, systolic blood pressure, trial intervention group, and calendar year of diagnosis